Susan G. Kornstein, MD

Long-Term Safety and Efficacy of Zuranolone in MDD

December 27, 2023

Most patients with MDD achieved response after 14 days of zuranolone treatment. For patients who responded to their first treatment, the time to repeat treatment was over 4 months.

Andrew J. Cutler, Gregory W. Mattingly, Susan G. Kornstein, et al

Original Research

Lisdexamfetamine Effects Based on Gender and Age

February 26, 2019

Lisdexamfetamine is approved to treat patients with binge eating disorder, but is it more effective in certain patient groups? This pooled analysis examines effects on the basis of gender...

Susan G. Kornstein, Caleb Bliss, Judith Kando, et al

Supplement Article

Epidemiology and Recognition of Binge-Eating Disorder in Psychiatry and Primary Care

January 25, 2017

Susan G. Kornstein

Article

Binge-Eating Disorder in the Clinical Setting

May 26, 2016

Although binge-eating disorder (BED) is the most prevalent eating disorder, it is underdiagnosed and undertreated. BED can be associated with medical and psychiatric comorbidities that, if left untreated, can...

Susan G. Kornstein, Jelena L. Kunovac, Barry K. Herman, et al

Original Research

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

November 26, 2013

Susan G. Kornstein, Ronald D. Pedersen, Peter J. Holland, et al

Article

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

October 15, 2013

Anita H. Clayton, Susan G. Kornstein, Boadie W. Dunlop, et al

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 27, 2013

John Zajecka, Susan G. Kornstein, Pierre Blier

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 15, 2013

John Zajecka, Susan G. Kornstein, Pierre Blier

Article

Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

August 15, 2010

Susan G. Kornstein, Qin Jiang, Sujana Reddy, et al

Original Research

Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-Being Outcome Measures in Patients With Major Depressive Disorder: A Pooled Analysis of 9 Double-Blind, Placebo-Controlled, 8-Week Clinical Trials

October 15, 2009

Claudio N. Soares, Susan G. Kornstein, Michael E. Thase, et al

Original Research

A Randomized, Double-Blind Study of Increasing or Maintaining Duloxetine Dose in Patients Without Remission of Major Depressive Disorder After Initial Duloxetine Therapy

September 30, 2008

Susan G. Kornstein, David L. Dunner, Adam L. Meyers, et al

Original Research

Implications of Pain in Generalized Anxiety Disorder: Efficacy of Duloxetine

June 16, 2008

James T. Hartford, Jean Endicott, Susan G. Kornstein, et al

Long-Term Safety and Efficacy of Zuranolone in MDD

Lisdexamfetamine Effects Based on Gender and Age

Epidemiology and Recognition of Binge-Eating Disorder in Psychiatry and Primary Care

Binge-Eating Disorder in the Clinical Setting

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-Being Outcome Measures in Patients With Major Depressive Disorder: A Pooled Analysis of 9 Double-Blind, Placebo-Controlled, 8-Week Clinical Trials

A Randomized, Double-Blind Study of Increasing or Maintaining Duloxetine Dose in Patients Without Remission of Major Depressive Disorder After Initial Duloxetine Therapy

Implications of Pain in Generalized Anxiety Disorder: Efficacy of Duloxetine

ELSEWHERE:

FOLLOW US:

Susan G. Kornstein, MD

Long-Term Safety and Efficacy of Zuranolone in MDD

Lisdexamfetamine Effects Based on Gender and Age

Epidemiology and Recognition of Binge-Eating Disorder in Psychiatry and Primary Care

Binge-Eating Disorder in the Clinical Setting

Influence of Sex and Menopausal Status on Response, Remission, and Recurrence in Patients With Recurrent Major Depressive Disorder Treated With Venlafaxine Extended Release or Fluoxetine: Analysis of Data From the PREVENT Study

Efficacy and Safety of Desvenlafaxine 50 mg/d in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Short-Term Efficacy and Safety of Desvenlafaxine in a Randomized, Placebo-Controlled Study of Perimenopausal and Postmenopausal Women With Major Depressive Disorder

Assessing the Efficacy of Desvenlafaxine for Improving Functioning and Well-Being Outcome Measures in Patients With Major Depressive Disorder: A Pooled Analysis of 9 Double-Blind, Placebo-Controlled, 8-Week Clinical Trials

A Randomized, Double-Blind Study of Increasing or Maintaining Duloxetine Dose in Patients Without Remission of Major Depressive Disorder After Initial Duloxetine Therapy

Implications of Pain in Generalized Anxiety Disorder: Efficacy of Duloxetine

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles